Business
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors ALACHUA, Fla., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc.
About this update from Axogen, Inc.
[{"type":"text","content":"Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors\n ALACHUA, Fla., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Paul G. Thomas has been appointed to its Board of Directors, effective September 30, 2020. Thomas will serve on both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. “Paul is an excellent addition to our board, as he brings more than 30 years of proven medical device and healthcare leadership experience in fast-growing biologic and pharmaceutical companies,” commented Karen Zaderej, chairman, CEO, and president. “We are excited for Paul to join our team, and we are looking forward to his informed insights as we pursue our shared goal of improving the quality of life for nerve repair patients.” Thomas currently serves on the board of directors of Abiomed, Inc. (NASDAQ: ABMD) and Surgalign Spine Technologies, Inc. (NASDAQ: SRGA). Thomas has more than 30 years of experience in the medtech industry and currently serves as the CEO and Co-Founder of Prominex, Inc. Thomas also served as the CEO of Roka Bioscience from 2009 to 2017. Prior to that, Thomas served as Chairman and CEO of LifeCell Corporation from 1998 until it was acquired by KCI in 2008 in a transaction valued at $1.8 billion. He also held various senior positions, including President of the Pharmaceutical Products Division, during his tenure of 15 years with Ohmeda, Inc. Thomas received his Master of Business Administration degree from Columbia University Graduate School of Business and completed his post graduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science. He received his Bachelor of Science degree in Chemistry from St. Michael’s College. “I look forward to working with Karen, the Board of Directors, and the Axogen team to continue helping surgeons improve quality of life for patients with nerve injuries by developing and advancing innovative nerve repair surgical solutions,” said Thomas. Thomas replaces outgoing Board member Robert J. Rudelius who resigned effective September 30, 2020 following ten years of service on the Axogen, Inc. Board of Directors. “I would lik...